RemeGen Secures NMPA Approval for Phase I/IIa Trial of Bispecific ADC RC288 in Solid Tumors
核心洞察
China's National Medical Products Administration has approved RemeGen's Phase I/IIa clinical trial application for RC288 (搜索), a bispecific antibody-drug conjugate targeting PSMA (搜索) and B7H3 (搜索) for advanced solid tumors.
The approval represents a strategic advancement in RemeGen's oncology pipeline and demonstrates innovation in next-generation ADC technologies for cancer treatment.
RC288 (搜索) will be tested as monotherapy in patients with locally advanced unresectable or metastatic malignant solid tumors (搜索) in the upcoming clinical trial.
RemeGen Co., Ltd. has received regulatory approval from China's National Medical Products Administration (NMPA) to initiate a Phase I/IIa clinical trial for RC288 (搜索), a novel bispecific antibody-drug conjugate targeting PSMA (搜索) and B7H3 (搜索). The investigational therapy will be evaluated as a monotherapy in patients with locally advanced unresectable or metastatic malignant solid tumors (搜索).
Novel Bispecific ADC Technology
RC288 (搜索) represents an advancement in next-generation antibody-drug conjugate technologies, combining dual targeting mechanisms through its bispecific design. The compound targets both prostate-specific membrane antigen (PSMA (搜索)) and B7H3 (搜索), two important cancer-associated antigens expressed across various solid tumor types.
The NMPA approval marks a strategic milestone in RemeGen's oncology pipeline development, underscoring the company's innovation capabilities in the competitive ADC therapeutic space. However, the company noted that while the trial clearance represents progress, it will not materially impact near-term financial performance and remains subject to the inherent risks, lengthy timelines, and uncertainties typical of early-stage pharmaceutical research and development.
Strong Commercial Performance Backdrop
The regulatory approval comes as RemeGen reported robust financial performance for 2025, with product sales revenue reaching approximately RMB2.31 billion, representing a 35.8% year-over-year increase. This growth was primarily driven by strong performance from the company's autoimmune therapy telitacicept and oncology drug disitamab vedotin, highlighting RemeGen's successful transition from a research-focused biotech to a commercial-stage pharmaceutical company.
Expanding Pipeline and Market Position
Beyond the RC288 (搜索) development, RemeGen has been advancing its lead asset telitacicept across multiple therapeutic indications. The company secured Chinese approval for generalized myasthenia gravis (搜索), obtained European Orphan Drug Designation, and achieved positive Phase III results in Sjögren's syndrome (搜索) and IgA nephropathy (搜索). Regulatory filings for these new indications have been accepted in China, with priority review granted for IgA nephropathy.
The inclusion of telitacicept for systemic lupus erythematosus (搜索) and generalized myasthenia gravis (搜索) in China's National Reimbursement Drug List further strengthens the commercial outlook. Additionally, an out-licensing agreement with a Nasdaq-listed partner demonstrates RemeGen's strategy to monetize its global intellectual property portfolio.
Clinical Development Strategy
The Phase I/IIa trial design for RC288 (搜索) will focus on establishing safety, tolerability, and preliminary efficacy signals in the target patient population of advanced solid tumor patients. The bispecific ADC approach aims to enhance therapeutic specificity while potentially reducing off-target effects compared to traditional single-target ADCs.
RemeGen's growing presence in both autoimmune diseases and oncology positions the company to capitalize on expanding market opportunities in China's innovative drug sector. The combination of strong commercial growth, expanding reimbursement coverage, and advancing clinical programs supports the company's strategy to broaden its market footprint and enhance long-term revenue visibility.